AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
愛文思控股的CAPItello第3期試驗在本地晚期/轉移性三陰性乳腺癌患者中使用Truqap（Capivasertib）與紫杉醇聯合治療，並未達到綜合生存率方面的主要雙重終點，與紫杉醇與安慰劑相比未有改善。
AstraZeneca's CAPItello Phase 3 Trial For Truqap (Capivasertib) Combined With Paclitaxel In Locally Advanced/Metastatic Triple-negative Breast Cancer Did Not Meet The Dual Primary Endpoints Of Improvement In Overall Survival Versus Paclitaxel Plus Placebo
愛文思控股的CAPItello第3期試驗在本地晚期/轉移性三陰性乳腺癌患者中使用Truqap（Capivasertib）與紫杉醇聯合治療，並未達到綜合生存率方面的主要雙重終點，與紫杉醇與安慰劑相比未有改善。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。